Pediatric Study Plans Would Be Required At End Of Phase II Under Bipartisan House Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Rather than assessing monetary penalties for violating study deadlines, H.R. 4274 directs FDA to issue warning letters and publish them on its website.